生物医药股INKT飙涨逾730%！公司宣布其药物在实体瘤治疗领域显示巨大潜力

老虎资讯综合

Jul 12, 2025

7月12日，MiNK Therapeutics飙涨730%，成交24.41亿美元。公司宣布其药物在实体瘤治疗领域显示巨大潜力。

这家致力于开发通用型恒定自然杀伤T细胞（iNKT）疗法的临床阶段生物制药公司宣布，其研究成果再次登上《自然·癌基因》期刊——报告显示一名对多种疗法无效的转移性睾丸癌患者在接受其通用型iNKT细胞疗法agenT-797治疗后，获得完全且持久的缓解。

治疗过程显示：该患者历经多线治疗均无效后，接受单次agenT-797输注联合百时美施贵宝Opdivo（纳武利尤单抗）治疗。患者最终实现临床、影像学和生化指标的完全缓解，两年多随访无疾病迹象。输注后六个月仍可检测到供体iNKT细胞，且治疗耐受性良好，未出现细胞因子释放综合征（CRS）或移植物抗宿主病（GVHD）。

该案例为日益丰富的临床证据再添力证，表明agenT-797在实体瘤治疗领域具有显著潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1112653329"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112653329\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112653329?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2025-07-12 07:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112653329","market":"us","top_or_hot":-1,"title":"生物医药股INKT飙涨逾730%！公司宣布其药物在实体瘤治疗领域显示巨大潜力","media":"老虎资讯综合","content":"<html><head></head><body><p>7月12日，<a href=\"https://laohu8.com/S/INKT\">MiNK Therapeutics</a>飙涨730%，成交24.41亿美元。公司宣布其药物在实体瘤治疗领域显示巨大潜力。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/71edb2321cdfe7ee341cf30cd694396e\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: start;\">这家致力于开发通用型恒定自然杀伤T细胞（iNKT）疗法的临床阶段生物制药公司宣布，其研究成果再次登上《自然·癌基因》期刊——报告显示一名对多种疗法无效的转移性睾丸癌患者在接受其通用型iNKT细胞疗法agenT-797治疗后，获得完全且持久的缓解。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f944850a6b41fe133e7ba8cc41891484\" tg-width=\"1099\" tg-height=\"693\"/></p><p style=\"text-align: start;\">治疗过程显示：该患者历经多线治疗均无效后，接受单次agenT-797输注联合百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a>Opdivo（纳武利尤单抗）治疗。患者最终实现临床、影像学和生化指标的完全缓解，两年多随访无疾病迹象。输注后六个月仍可检测到供体iNKT细胞，且治疗耐受性良好，未出现细胞因子释放综合征（CRS）或移植物抗宿主病（GVHD）。</p><p style=\"text-align: start;\">该案例为日益丰富的临床证据再添力证，表明agenT-797在实体瘤治疗领域具有显著潜力。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生物医药股INKT飙涨逾730%！公司宣布其药物在实体瘤治疗领域显示巨大潜力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生物医药股INKT飙涨逾730%！公司宣布其药物在实体瘤治疗领域显示巨大潜力\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-07-12 07:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>7月12日，<a href=\"https://laohu8.com/S/INKT\">MiNK Therapeutics</a>飙涨730%，成交24.41亿美元。公司宣布其药物在实体瘤治疗领域显示巨大潜力。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/71edb2321cdfe7ee341cf30cd694396e\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: start;\">这家致力于开发通用型恒定自然杀伤T细胞（iNKT）疗法的临床阶段生物制药公司宣布，其研究成果再次登上《自然·癌基因》期刊——报告显示一名对多种疗法无效的转移性睾丸癌患者在接受其通用型iNKT细胞疗法agenT-797治疗后，获得完全且持久的缓解。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f944850a6b41fe133e7ba8cc41891484\" tg-width=\"1099\" tg-height=\"693\"/></p><p style=\"text-align: start;\">治疗过程显示：该患者历经多线治疗均无效后，接受单次agenT-797输注联合百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a>Opdivo（纳武利尤单抗）治疗。患者最终实现临床、影像学和生化指标的完全缓解，两年多随访无疾病迹象。输注后六个月仍可检测到供体iNKT细胞，且治疗耐受性良好，未出现细胞因子释放综合征（CRS）或移植物抗宿主病（GVHD）。</p><p style=\"text-align: start;\">该案例为日益丰富的临床证据再添力证，表明agenT-797在实体瘤治疗领域具有显著潜力。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INKT","symbol_name":"MiNK Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1112653329","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112653329","pubTimestamp":1752276241,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"7月12日，$MiNK Therapeutics$飙涨730%，成交24.41亿美元。治疗过程显示：该患者历经多线治疗均无效后，接受单次agenT-797输注联合百时美$施贵宝$Opdivo治疗。该案例为日益丰富的临床证据再添力证，表明agenT-797在实体瘤治疗领域具有显著潜力。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"INKT":"MiNK Therapeutics, Inc."},"translate_title":"Biopharmaceutical stock INKT soared more than 730%! The company announces that its drug shows great potential in the treatment of solid tumors","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/c5442079f83edb375317650e4165607c","symbols_score_info":{"INKT":1},"content_text":"7月12日，MiNK Therapeutics飙涨730%，成交24.41亿美元。公司宣布其药物在实体瘤治疗领域显示巨大潜力。这家致力于开发通用型恒定自然杀伤T细胞（iNKT）疗法的临床阶段生物制药公司宣布，其研究成果再次登上《自然·癌基因》期刊——报告显示一名对多种疗法无效的转移性睾丸癌患者在接受其通用型iNKT细胞疗法agenT-797治疗后，获得完全且持久的缓解。治疗过程显示：该患者历经多线治疗均无效后，接受单次agenT-797输注联合百时美施贵宝Opdivo（纳武利尤单抗）治疗。患者最终实现临床、影像学和生化指标的完全缓解，两年多随访无疾病迹象。输注后六个月仍可检测到供体iNKT细胞，且治疗耐受性良好，未出现细胞因子释放综合征（CRS）或移植物抗宿主病（GVHD）。该案例为日益丰富的临床证据再添力证，表明agenT-797在实体瘤治疗领域具有显著潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}